THU0452 PREVALENCE OF AXIAL OSTEOARTHRITIS IN SPAIN: EPISER-2016
Authors: Maite Silva-Díaz, Víctor Quevedo Vila, Daniel Seoane Mato, Sagrario Bustabad, Francisco J. Blanco
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Osteoarthritis (OA) is a heterogeneous group of diseases with common clinical and radiographic manifestations involving the peripheral and axial skeletal. OA is the most prevalent rheumatic disease however, there are very few publications focused in axial OA. In 2016, the Spanish Society of Rheumatology (SER) started a population descriptive study (EPISER 2016) to analyze the prevalence of 13 rheumatic diseases in Spain, including peripherical (hip, knee and hand) and axial (cervical and lumbar spine) OA. <h3>Objectives:</h3> To estimate in adult population the prevalence in Spain of symptomatic axial OA (cervical and lumbar spine) and associated factors. <h3>Methods:</h3> EPISER 2016 study is a cross-sectional, population-based descriptive study. To estimate the OA prevalence, adult population aged 40 or older was selected. The initial recruitment was made through by a call center. Participants who met the premises of an initial screening based on symptoms were also identified. In a second phase rheumatologists confirmed the diagnosis. The axial OA diagnostic criteria to confirm new diagnosis were both clinical and radiographic criteria. Clinical criteria: mechanical pain longer than 3 months of evolution and stiffness of less than 30 minutes or absence of it; and radiographic criteria: vertebral osteophytes or reduction of intervertebral space with sclerosis of vertebral plate and sclerosis in interapofisary joints. To confirm the diagnosis, it was necessary that both clinical criteria and at least one radiographic criteria were met. <h3>Results:</h3> The sample of the EPISER study was 3,336 subjects ≥ 40, of whom 978 had peripherical or axial OA. The mean age was 64.72 years, 730 were women, 62.6% had basic education, 64,8% were overweight or obese and 83,9% were ex-smokers or non-smokers (Figure 1). The prevalence of global OA (peripheral+axial) was 29.35%. Prevalence of peripherical and axial OA was 19,62% and 19,17% respectively. The characteristics of patients with peripheral and axial OA follow similar patterns. Both types of OA are more frequent in women with basic education levels. Regarding age, there are more patients with axial osteoarthritis between 40-49 years than with peripheral OA. Obesity or overweight are more strongly associated with peripheral OA. Prevalence of cervical OA was 10.10%. In the multivariate analysis, it was observed that cervical OA is more frequent in women and older subjects, with the prevalence peak between 60-69 years. It is also more frequent in subjects with obesity and in subjects with a basic education level (Figure 2). OA cervical prevalence is lower in subjects from northern Spain than in population from the Mediterranean area (including the Canary Islands) and central Spain. Smoking, living in a rural or urban environment or having been born abroad were not associated with cervical OA. Prevalence of lumbar OA was 15.52%. Multivariate analysis also showed that lumbar OA is more frequent in women and it increases with age (prevalence peak in ≥80 years). Greater association was observed with obesity or overweight and with basic study levels. Lumbar OA prevalence was higher in population from centre of Spain compared with other areas. Tobacco consumption, living in a rural or urban environment or having been born abroad were not associated with lumbar OA. <h3>Conclusion:</h3> EPISER2016 study shows similar prevalence of peripherical and axial OA. Lumbar OA is more prevalent than cervical OA. Axial OA in Spain is more frequent in women, increases with age with a peak between 60-69 years for cervical OA and ≥ 80 years for lumbar OA. Both cervical and lumbar OA are more frequent in patients with obesity or overweight and with basic studies. <h3>Disclosure of Interests:</h3> Maite Silva-Díaz: None declared, Víctor Quevedo Vila: None declared, Daniel Seoane Mato: None declared, Sagrario Bustabad: None declared, Francisco J. Blanco Consultant for: AbbVie, Bioiberica, BMS, GSK, Grünenthal, Janssen, Lilly, Pfizer, Regeneron, Roche, Sanofi, TRB Chemedica, and UCB, Grupo de trabajo proyecto EPISER2016: None declared